{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:54:53Z","timestamp":1787849693161,"version":"build-2784847793"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Anaplastic thyroid cancer (ATC) is a highly lethal disease, often diagnosed with advanced locoregional and distant metastases, resulting in a median survival of just 3\u20135 months. This study determines the stratified effectiveness of baseline treatments in all combinations, enabling precise prognoses prediction and establishing benchmarks for advanced therapeutic options.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The study extracted a cohort of pathologically confirmed ATC patients from the Surveillance, Epidemiology, and End Results program. Overall, 1879 patients from 2000 to 2018 were identified from the database. Kaplan\u2013Meier survival curve estimation and Cox proportional hazard regression were applied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall, compared with no treatment, surgery raised 1-year overall survival (OS) from 0.6% to 30% and median survival from &lt;1 month to 3 months in ATC patients. For stage IVa, surgery increased 1-year OS from 21.5% to 71.8% and median survival from 2 to 23.5 months, and in stage IVb, surgery increased 1-year OS from 9.4% to 41.3% and median survival from 2 to 7 months; however, in stage IVc, the benefits of surgery were not markedly different from non-surgical approaches. When combined with surgery, other effective non-surgical ATC treatments demonstrated a surgery-dominant synergistic effect, particularly for stages IVa and IVb ATC, but not for stage IVc ATC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our study provides insights into stratified baseline treatments for patients with ATC in all stages, emphasizing surgery\u2019s vital role in a multimodal approach.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-024-16852-y","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T20:31:56Z","timestamp":1738009916000},"page":"2732-2742","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Stratified Impact of Therapies on Anaplastic Thyroid Cancer Outcomes in the Pre-Gene-Targeted Therapy Era"],"prefix":"10.1245","volume":"32","author":[{"given":"Kun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anping","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2382-8444","authenticated-orcid":false,"given":"Ya-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"issue":"12","key":"16852_CR1","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1210\/jc.2017-01180","volume":"102","author":"N Prasongsook","year":"2017","unstructured":"Prasongsook N, Kumar A, Chintakuntlawar AV, et al. Survival in response to multimodal therapy in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2017;102(12):4506\u201314. https:\/\/doi.org\/10.1210\/jc.2017-01180.","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"16852_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/EJE-16-0574","volume":"175","author":"J Wendler","year":"2016","unstructured":"Wendler J, Kroiss M, Gast K, et al. Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. Eur J Endocrinol. 2016;175(6):521\u20139. https:\/\/doi.org\/10.1530\/EJE-16-0574.","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"16852_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J, et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2021;31(3):337\u201386. https:\/\/doi.org\/10.1089\/thy.2020.0944.","journal-title":"Thyroid."},{"issue":"Suppl 7","key":"16852_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/annonc\/mds230","volume":"23","author":"F Pacini","year":"2012","unstructured":"Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):110\u20139. https:\/\/doi.org\/10.1093\/annonc\/mds230.","journal-title":"Ann Oncol."},{"issue":"6","key":"16852_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol). 2010;22(6):486\u201397. https:\/\/doi.org\/10.1016\/j.clon.2010.03.013.","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"1","key":"16852_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-018-0903-0","volume":"17","author":"S Saini","year":"2018","unstructured":"Saini S, Tulla K, Maker AV, Burman KD, Prabhakar BS. Therapeutic advances in anaplastic thyroid cancer: a current perspective. Mol Cancer. 2018;17(1):154. https:\/\/doi.org\/10.1186\/s12943-018-0903-0.","journal-title":"Mol Cancer."},{"issue":"23","key":"16852_CR7","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMc1613118","volume":"375","author":"JA Fagin","year":"2016","unstructured":"Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(23):2307. https:\/\/doi.org\/10.1056\/NEJMc1613118.","journal-title":"N Engl J Med."},{"issue":"1","key":"16852_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1272\/jnms.2018_85-3","volume":"85","author":"I Sugitani","year":"2018","unstructured":"Sugitani I, Onoda N, Ito KI, Suzuki S. Management of anaplastic thyroid carcinoma: the fruits from the ATC research consortium of Japan. J Nippon Med Sch. 2018;85(1):18\u201327. https:\/\/doi.org\/10.1272\/jnms.2018_85-3.","journal-title":"J Nippon Med Sch."},{"issue":"3","key":"16852_CR9","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/ERC-17-0435","volume":"25","author":"V Tiedje","year":"2018","unstructured":"Tiedje V, Stuschke M, Weber F, Dralle H, Moss L, Fuhrer D. Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer. 2018;25(3):R153\u201361. https:\/\/doi.org\/10.1530\/ERC-17-0435.","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"16852_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","volume":"36","author":"V Subbiah","year":"2018","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7\u201313. https:\/\/doi.org\/10.1200\/JCO.2017.73.6785.","journal-title":"J Clin Oncol."},{"issue":"4","key":"16852_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014.","journal-title":"Ann Oncol."},{"issue":"6","key":"16852_CR12","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1210\/er.2019-00007","volume":"40","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Ryder M, Jimenez C. Targeted therapy for advanced thyroid cancer: kinase inhibitors and beyond. Endocr Rev. 2019;40(6):1573\u2013604. https:\/\/doi.org\/10.1210\/er.2019-00007.","journal-title":"Endocr Rev."},{"issue":"7","key":"16852_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1406470.","journal-title":"N Engl J Med."},{"issue":"23","key":"16852_CR14","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1200\/JCO.19.02727","volume":"38","author":"J Capdevila","year":"2020","unstructured":"Capdevila J, Wirth LJ, Ernst T, et al. PD-1 blockade in anaplastic thyroid carcinoma. J Clin Oncol. 2020;38(23):2620\u20137. https:\/\/doi.org\/10.1200\/JCO.19.02727.","journal-title":"J Clin Oncol."},{"issue":"7","key":"16852_CR15","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1089\/thy.2020.0322","volume":"31","author":"C Dierks","year":"2021","unstructured":"Dierks C, Seufert J, Aumann K, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31(7):1076\u201385. https:\/\/doi.org\/10.1089\/thy.2020.0322.","journal-title":"Thyroid."},{"issue":"7","key":"16852_CR16","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/cancers11070943","volume":"11","author":"J Ljubas","year":"2019","unstructured":"Ljubas J, Ovesen T, Rusan M. A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer. Cancers (Basel). 2019;11(7):947. https:\/\/doi.org\/10.3390\/cancers11070943.","journal-title":"Cancers (Basel)."},{"issue":"10387","key":"16852_CR17","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","volume":"401","author":"DW Chen","year":"2023","unstructured":"Chen DW, Lang BHH, McLeod DSA, Newbold K, Haymart MR. Thyroid cancer. Lancet. 2023;401(10387):1531\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)00020-X.","journal-title":"Lancet."},{"key":"16852_CR18","unstructured":"Overview of the SEER Program-Incidence-SEER Research Plus Data, 18 Registries, Nov 2020 Sub (2000-2018). Available at: https:\/\/seer.cancer.gov\/data-software\/documentation\/seerstat\/nov2020\/. Accessed 9 Oct 2021."},{"issue":"9596","key":"16852_CR19","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","volume":"370","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet."},{"key":"16852_CR20","doi-asserted-by":"publisher","first-page":"882579","DOI":"10.3389\/fendo.2022.882579","volume":"13","author":"K Zhang","year":"2022","unstructured":"Zhang K, Su A, Wang X, et al. Non-linear correlation between tumor size and survival outcomes for parathyroid Carcinoma: a SEER population-based cohort study. Front Endocrinol (Lausanne). 2022;13:882579. https:\/\/doi.org\/10.3389\/fendo.2022.882579.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"16852_CR21","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1097\/AS9.0000000000000226","volume":"3","author":"K Zhang","year":"2022","unstructured":"Zhang K, Peng X, Wei T, Li Z, Zhu J, Chen YW. Prognostic nomogram and competing risk analysis of death for primary thyroid lymphoma: a long-term survival study of 1638 patients. Ann Surg Open. 2022;3(4):e226. https:\/\/doi.org\/10.1097\/AS9.0000000000000226.","journal-title":"Ann Surg Open."},{"issue":"9","key":"16852_CR22","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas A, Dadu R, Busaidy NL, et al. Evaluation of overall survival in patients with anaplastic thyroid Carcinoma, 2000\u20132019. JAMA Oncol. 2020;6(9):1397\u2013404. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362.","journal-title":"JAMA Oncol."},{"issue":"1","key":"16852_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12094-016-1506-0","volume":"19","author":"P Jimenez-Fonseca","year":"2017","unstructured":"Jimenez-Fonseca P, Gomez Saez JM, Santamaria Sandi J, et al. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma. Clin Transl Oncol. 2017;19(1):12\u201320. https:\/\/doi.org\/10.1007\/s12094-016-1506-0.","journal-title":"Clin Transl Oncol."},{"issue":"6","key":"16852_CR24","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","volume":"36","author":"I Sugitani","year":"2012","unstructured":"Sugitani I, Miyauchi A, Sugino K, Okamoto T, Yoshida A, Suzuki S. Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients. World J Surg. 2012;36(6):1247\u201354. https:\/\/doi.org\/10.1007\/s00268-012-1437-z.","journal-title":"World J Surg."},{"issue":"4","key":"16852_CR25","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao X, Wang JR, Dadu R, et al. Surgery after BRAF-directed therapy is associated with improved survival in BRAF (V600E) mutant anaplastic thyroid cancer: a single-center retrospective cohort study. Thyroid. 2023;33(4):484\u201391. https:\/\/doi.org\/10.1089\/thy.2022.0504.","journal-title":"Thyroid"},{"issue":"3","key":"16852_CR26","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1089\/thy.2023.0573","volume":"34","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Iyer PC, Dadu R, et al. Checkpoint Inhibition in Addition to Dabrafenib\/Trametinib for BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma. Thyroid. 2024;34(3):336\u201346. https:\/\/doi.org\/10.1089\/thy.2023.0573.","journal-title":"Thyroid."},{"issue":"2","key":"16852_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/cncr.32548","volume":"126","author":"D Fan","year":"2020","unstructured":"Fan D, Ma J, Bell AC, et al. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer. 2020;126(2):444\u201352. https:\/\/doi.org\/10.1002\/cncr.32548.","journal-title":"Cancer."},{"key":"16852_CR28","doi-asserted-by":"publisher","first-page":"8218949","DOI":"10.1155\/2019\/8218949","volume":"2019","author":"KL Corrigan","year":"2019","unstructured":"Corrigan KL, Williamson H, Elliott Range D, Niedzwiecki D, Brizel DM, Mowery YM. Treatment outcomes in anaplastic thyroid cancer. J Thyroid Res. 2019;2019:8218949. https:\/\/doi.org\/10.1155\/2019\/8218949.","journal-title":"J Thyroid Res."},{"issue":"8","key":"16852_CR29","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/cancers11081188","volume":"11","author":"J Simoes-Pereira","year":"2019","unstructured":"Simoes-Pereira J, Capitao R, Limbert E, Leite V. Anaplastic thyroid cancer: clinical picture of the last two decades at a single oncology referral centre and novel therapeutic options. Cancers (Basel). 2019;11(8):1188. https:\/\/doi.org\/10.3390\/cancers11081188.","journal-title":"Cancers (Basel)."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16852-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-16852-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-16852-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T17:28:16Z","timestamp":1741195696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-16852-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["16852"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-16852-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]},"assertion":[{"value":"10 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kun Zhang, Xinyi Wang, Jianyong Lei, Anping Su, Tao Wei, Zhihui Li, and Ya-Wen Chen have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}